Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

THYROID DISEASE

Step-down steroid-sparing therapy in active thyroid eye disease

Intravenous steroid therapy in thyroid eye disease has limitations and is potentially harmful at high doses. A steroid-sparing approach is a reasonable option, but combination therapy must be tested in randomized clinical trials designed to establish the efficacy and the potentially increased risk of adverse effects of combined immunosuppressive treatment.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bartalena, L. et al. The 2016 European Thyroid Association/European Group on Graves’ orbitopathy — guidelines for the management of Graves’ orbitopathy. Eur. Thyroid J. 5, 9–26 (2016).

    Article  CAS  Google Scholar 

  2. Bartalena, L. et al. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves’ orbitopathy. J. Clin. Endocrinol. Metab. 97, 4454–4463 (2012).

    Article  CAS  Google Scholar 

  3. Sipkova, Z. et al. Early use of steroid-sparing agents in the inactivation of moderate-to-severe active thyroid eye disease; a step-down approach. Clin. Endocrinol. https://doi.org/10.1111/cen.13834 (2018).

    Article  Google Scholar 

  4. Perros, P., Crombie, A. L. & Kendall-Taylor, P. Natural history of thyroid associated ophthalmopathy. Clin. Endocrinol. 42, 45–50 (1995).

    Article  CAS  Google Scholar 

  5. Goekoop-Ruiterman, Y. P. et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). Ann. Rheum. Dis. 66, 1227–1232 (2007).

    Article  Google Scholar 

  6. Kahaly, G. et al. Cyclosporin and prednisone v. prednisone in treatment of Graves’ ophthalmopathy: a controlled, randomized and prospective study. Eur. J. Clin. Invest. 16, 415–422 (1986).

    Article  CAS  Google Scholar 

  7. Prummel, M. F. et al. Prednisone and cyclosporine in the treatment of severe Graves’ ophthalmopathy. N. Engl. J. Med. 321, 1353–1359 (1989).

    Article  CAS  Google Scholar 

  8. Kahaly, G. J. et al. Mycophenolate plus methylprednisolone versus methylprednisolone alone in active, moderate-to-severe Graves’ orbitopathy (MINGO): a randomised, observer-masked, multicentre trial. Lancet Diabetes Endocrinol. 6, 287–298 (2018).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was in part supported by Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan Italy.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Mario Salvi.

Ethics declarations

Competing interests

The author declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Salvi, M. Step-down steroid-sparing therapy in active thyroid eye disease. Nat Rev Endocrinol 14, 634–635 (2018). https://doi.org/10.1038/s41574-018-0099-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41574-018-0099-9

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing